Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
NCT05834478 · View on ClinicalTrials.gov ↗
Study Summary
This study is being done to answer the question: what is the effect of Vagal Nerve Stimulation (VNS) dosing on opioid withdrawal responses in individuals with a history of Opioid Use Disorders (OUDs)? Eligible participants will be in the study for one week in an inpatient research hospital stay, have an MRI scan, and have a follow-up call 1-3 months after their inpatient stay. Participants will complete several psychiatric questionnaires/interviews, physiological monitoring with several devices, brain imaging, and VNS testing.
Conditions Studied
Interventions
- DEVICE Sham Stimulation
- DEVICE Transcutaneous Cervical Vagal Nerve Stimulation
- DRUG [F-18]Fallypride
Study Locations (6)
Georgia
- Emory University Clinical Research Network — Atlanta
- Health Sciences Research Building — Atlanta
- Rollins School of Public Health — Atlanta
- 12 Executive Park Drive — Atlanta
- Emory Univeristy — Atlanta
- Georgia Institute of Technology — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05834478
The ClinicalTrials.gov registry entry for NCT05834478 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions — of which Sham Stimulation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05834478 reports 6 study locations spanning 1 distinct geographic area — top geographies include Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05834478 about?
NCT05834478 is a clinical study titled "Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3". This study is being done to answer the question: what is the effect of Vagal Nerve Stimulation (VNS) dosing on opioid withdrawal responses in individuals with a history of Opioid Use Disorders (OUDs)? Eligible participants will be in the study for one week in an inpatient research hospital stay, hav...
What is the current status of trial NCT05834478?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2024-02-20. Estimated completion is 2026-12.
What conditions does trial NCT05834478 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Use, Withdrawal Symptoms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05834478?
The interventions under investigation include: Sham Stimulation (DEVICE), Transcutaneous Cervical Vagal Nerve Stimulation (DEVICE), [F-18]Fallypride (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05834478?
This trial is sponsored by Emory University, which has 1,434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05834478 being conducted?
This trial has 6 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.